Clinical Trial Update: Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating an immune response modifier for breast, ovarian, endometrial, and cervical cancers has completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Breast Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2009-09-25